Navidea Biopharmaceuticals (NYSE: NAVB) reported Q2 EPS of ($0.09), $0.02 worse than the analyst estimate of ($0.07). Revenue for the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE